MX375402B - Nuevo anticuerpo anti-dengue de espectro completo. - Google Patents

Nuevo anticuerpo anti-dengue de espectro completo.

Info

Publication number
MX375402B
MX375402B MX2016009991A MX2016009991A MX375402B MX 375402 B MX375402 B MX 375402B MX 2016009991 A MX2016009991 A MX 2016009991A MX 2016009991 A MX2016009991 A MX 2016009991A MX 375402 B MX375402 B MX 375402B
Authority
MX
Mexico
Prior art keywords
antibody agents
new full
spectrum anti
dengue antibody
serotypes
Prior art date
Application number
MX2016009991A
Other languages
English (en)
Spanish (es)
Other versions
MX2016009991A (es
Inventor
Kannan Tharakaraman
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2016009991A publication Critical patent/MX2016009991A/es
Publication of MX375402B publication Critical patent/MX375402B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016009991A 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo. MX375402B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11
PCT/US2015/015510 WO2015123362A1 (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Publications (2)

Publication Number Publication Date
MX2016009991A MX2016009991A (es) 2016-10-07
MX375402B true MX375402B (es) 2025-03-06

Family

ID=53800606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009991A MX375402B (es) 2014-02-11 2015-02-11 Nuevo anticuerpo anti-dengue de espectro completo.

Country Status (12)

Country Link
US (3) US9902764B2 (cg-RX-API-DMAC7.html)
EP (1) EP3104888A4 (cg-RX-API-DMAC7.html)
JP (1) JP6707455B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160119806A (cg-RX-API-DMAC7.html)
CN (1) CN106413749B (cg-RX-API-DMAC7.html)
AU (1) AU2015217149B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016017764A2 (cg-RX-API-DMAC7.html)
CA (1) CA2938495A1 (cg-RX-API-DMAC7.html)
IL (1) IL246788A0 (cg-RX-API-DMAC7.html)
MX (1) MX375402B (cg-RX-API-DMAC7.html)
SG (2) SG11201606163QA (cg-RX-API-DMAC7.html)
WO (1) WO2015123362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
JP7508368B2 (ja) 2018-03-15 2024-07-01 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
CA2548808C (en) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
WO2009098450A2 (en) 2008-02-05 2009-08-13 Medical Research Council Methods and compositions
CN102197050A (zh) * 2008-10-05 2011-09-21 小利兰斯坦福大学理事会 丙型肝炎抗体和其用途
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
AU2009322185A1 (en) 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
SG173482A1 (en) 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) * 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
AU2013299986B2 (en) * 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
US9902764B2 (en) * 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도

Also Published As

Publication number Publication date
EP3104888A4 (en) 2017-08-09
EP3104888A1 (en) 2016-12-21
SG10201807826XA (en) 2018-10-30
US20180237504A1 (en) 2018-08-23
AU2015217149A1 (en) 2016-09-08
US11421018B2 (en) 2022-08-23
US9902764B2 (en) 2018-02-27
CN106413749B (zh) 2022-04-05
WO2015123362A1 (en) 2015-08-20
AU2015217149B2 (en) 2020-09-10
US10519220B2 (en) 2019-12-31
JP6707455B2 (ja) 2020-06-10
US20200207841A1 (en) 2020-07-02
BR112016017764A2 (pt) 2017-10-10
MX2016009991A (es) 2016-10-07
KR20160119806A (ko) 2016-10-14
IL246788A0 (en) 2016-08-31
CA2938495A1 (en) 2015-08-20
US20150368321A1 (en) 2015-12-24
CN106413749A (zh) 2017-02-15
JP2017507131A (ja) 2017-03-16
SG11201606163QA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
MX375402B (es) Nuevo anticuerpo anti-dengue de espectro completo.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX388181B (es) Anticuerpos anti-pd-1.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA201891992A1 (ru) Химерные рецепторы и способы их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
PH12016501366A1 (en) Novel anti-baff antibodies
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
PE20170765A1 (es) Moleculas de union tri-especificas y metodos de uso de las mismas
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
NZ759835A (en) Cd38 modulating antibody
EA201590918A1 (ru) Антитела к bmp-6
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن

Legal Events

Date Code Title Description
FG Grant or registration